Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Novartis in $1 Billion Deal for DTx Pharma, an siRNA Company Incubated by Viva BioInnovator

publication date: Jul 19, 2023

Novartis signed a $1 billion agreement to acquire DTx Pharma, a preclinical San-Diego company developing siRNA therapies for neuroscience indications. DTx was invested and incubated by Viva BioInnovator, a San Diego-China CRO/incubator that develops biotech start-ups in China and the US. The incubator is an arm of Shanghai’s Viva Biotech, which offers full-service CRO/CDMO services. DTx’s lead program is a preclinical siRNA aimed at Charcot-Marie-Tooth Disease Type 1A (CMT1A). DTx Pharma shareholders will receive $500 million upfront and up to $500 million in milestones. More details....

Stock Symbol: (NYSE: NVS)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital